Autorisation d’accès précoce refusée à la spécialité TEPEZZA (téprotumumab) dans l'indication « traitement des patients adultes atteints d’ophtalmopathie basedowienne modérée à sévère ».
See also
HAS opinions and decisions
26/02/2025
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
FG4aUeVYwNjP4mjk
